We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Dynavax Awarded Grant to Support Development of TLR Inhibitors in Skin Diseases
News

Dynavax Awarded Grant to Support Development of TLR Inhibitors in Skin Diseases

Dynavax Awarded Grant to Support Development of TLR Inhibitors in Skin Diseases
News

Dynavax Awarded Grant to Support Development of TLR Inhibitors in Skin Diseases

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Dynavax Awarded Grant to Support Development of TLR Inhibitors in Skin Diseases"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Dynavax Technologies Corporation has announced the award of a Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID).

The grant will support the preclinical development of Dynavax’s first-in-class oligonucleotide-based Toll-like Receptor (TLR) inhibitors for use in inflammatory skin diseases such as psoriasis, cutaneous lupus, and dermatomyositis. This new two-year $700,000 grant is in addition to a $1.8 million grant awarded in 2008.

“In addition to validating our proprietary technology, this new grant supports the preclinical studies for our TLR inhibitors, which represent a novel therapeutic approach for the treatment of inflammatory skin disorders,” commented Robert L. Coffman, Ph.D., Vice President and Chief Scientific Officer of Dynavax Technologies. “Grant funding and partnerships with leading pharmaceutical companies help us advance the development of our TLR-based products targeting significant unmet medical needs.”
Advertisement